Breast Cancer

Videos

Breast cancer experts review unmet needs in the management of HER2+ metastatic breast cancer and updates from the 2021 ASCO virtual meeting.

Updates From ASCO 2021 for HER2+ Breast Cancer

Neil Iyengar, MD, leads the discussion on the current standard of care and the sequencing of therapy for HER2+ metastatic breast cancer.

Standard of Care for HER2+ Metastatic Breast Cancer

Cynthia Ma, MD, PhD, explains key efficacy findings regarding HER-targeted therapy to treat patients with HER2-mutant breast cancer. 

Cynthia Ma, MD, PhD, Discusses Results From a Phase 2 Trial of Neratinib/Fulvestrant in HER2-Mutant Breast Cancer

An expert in treating breast cancer discusses potential therapy options for patients with HER2-mutant. 

Cynthia Ma, MD, PhD, Discusses HER2-Targeted Therapy for Patients with HER2-Mutant Breast Cancer

Articles

A dose-escalation schedule for neratinib may help some patients with HER2-positive breast cancer better manage severe diarrhea resulting from treatment. 

FDA Approves Dose-Escalation Label Amendment for Neratinib in HER2+ Breast Cancer 

Data from the phase 3 TULIP trial showed that [vic-]trastuzumab duocarmazine yielded positive progression-free survival for patients with pretreated HER2-positive metastatic breast cancer.

Positive Topline Survival Data Observed in Phase 3 Trial of SYD985 for HER2-Positive Metastatic Breast Cancer

18FDG-PET was successful in identifying patients with HER2-positive early-stage breast cancer who were more likely to benefit from chemotherapy-free treatment with trastuzumab and pertuzumab. 

18FDG-PET May Identify Patients With HER2-Positive Early Breast Cancer Benefiting from Chemo-Free HER2 Blockade

Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.

Numerically Improved pCR Not Significant With SD-101 Plus Pembrolizumab in HER2– Breast Cancer

With a de-escalation strategy for administration of trastuzumab and pertuzumab in the neoadjuvant setting, patients with HER2-positive, hormone receptor–negative breast cancer experienced high rates of response and survival.

De-escalated Neoadjuvant Trastuzumab/Pertuzumab Induced Sufficient Responses in HER2+/HR– Breast Cancer

A 3-year follow-up analysis of event-free and overall survival revealed similar results for patients with stage II or III ERBB2-positive breast cancer treated with either neoadjuvant anthracycline and nonanthracycline treatment regimens.

HER2-Positive Breast Cancer | Topics